Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more to come. Under the renewed distribution agreement, Ewopharma continues to manage market access and the targeted promotion of Dr. Falk Pharma’s gastroenterological product portfolio through gastroenterologists across more than 10 markets in Central Eastern Europa and Adriatics. The contract renewal sends a strong signal of shared growth – and a clear commitment to one of the most enduring partnerships in the region.
What sets this partnership apart is its depth: Trust built over decades, shared values, and an unwavering focus on the needs of patients. Ewopharma’s profound market knowledge, well-established network among gastroenterologists, and strong local presence in the region have been instrumental in sustainably positioning and advancing Dr. Falk Pharma’s innovative therapies.
Alain Staub, CEO and President of the Board of Directors of Ewopharma, comments: “This partnership is far more than a contract – it is the result of decades of shared work, common values, and genuine trust. By extending our collaboration for the long term, we are sending a clear message: Together, we are committed to reaching even more patients across Central Eastern Europe with high-quality gastroenterological therapies.”
Torben Zachmann, Managing Director Commercial of Dr. Falk Pharma, adds: “The renewal of our partnership with Ewopharma is a clear reflection of the success we have built together. Ewopharma understands our products, our values, and the needs of patients in the region – and that is a foundation on which we will continue to grow. We look forward to the next chapter of this partnership with great confidence.”
The contract renewal marks a further milestone in the international growth strategy of both companies and reaffirms their shared commitment to ensuring patients in Central Eastern Europe and Adriatics continue to have access to the best possible gastroenterological therapies.
About Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. The Falk Group employs approximately 1550 individuals globally and 450 in Freiburg. Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com .
What sets this partnership apart is its depth: Trust built over decades, shared values, and an unwavering focus on the needs of patients. Ewopharma’s profound market knowledge, well-established network among gastroenterologists, and strong local presence in the region have been instrumental in sustainably positioning and advancing Dr. Falk Pharma’s innovative therapies.
Alain Staub, CEO and President of the Board of Directors of Ewopharma, comments: “This partnership is far more than a contract – it is the result of decades of shared work, common values, and genuine trust. By extending our collaboration for the long term, we are sending a clear message: Together, we are committed to reaching even more patients across Central Eastern Europe with high-quality gastroenterological therapies.”
Torben Zachmann, Managing Director Commercial of Dr. Falk Pharma, adds: “The renewal of our partnership with Ewopharma is a clear reflection of the success we have built together. Ewopharma understands our products, our values, and the needs of patients in the region – and that is a foundation on which we will continue to grow. We look forward to the next chapter of this partnership with great confidence.”
The contract renewal marks a further milestone in the international growth strategy of both companies and reaffirms their shared commitment to ensuring patients in Central Eastern Europe and Adriatics continue to have access to the best possible gastroenterological therapies.
About Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. The Falk Group employs approximately 1550 individuals globally and 450 in Freiburg. Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com .
